The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC

British Journal of Cancer

Volumn 110, Issue 2, 2014, Pages 363-368

  Nygaard, A D ^a   Holdgaard, P C ^a   Spindler, K L G ^a   Pallisgaard, N ^a   Jakobsen, A ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

cell free DNA; cfDNA; metabolism; non small cell lung cancer; NSCLC; PET CT; prognosis; tumour volume

Indexed keywords

CELL FREE DNA; DNA; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLYCOLYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METABOLIC TUMOR VOLUME; MIDDLE AGED; OVERALL SURVIVAL; PET-CT SCANNER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL TIME; TOTAL LESION GLYCOLYSIS; TUMOR VOLUME; VERY ELDERLY; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NON SMALL CELL LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; STANDARDIZED UPTAKE VALUE;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84892910082     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.705     Document Type: Article

References (31)

1. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37: 181-200.
2. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF (2012) Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 264: 559-566.
3. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368: 1199-1209.
4. De Mattos-Arruda L, Olmos D, Tabernero J (2011) Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Future Oncol 7: 1385-1397.
5. De MM, Klatte T, Haitel A, Marberger M (2011) Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer 118: 82-90.
6. Ellinger J, Muller SC, Stadler TC, Jung A, RA VON, Bastian PJ (2011) The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol 29: 124-129.
7. Gorenstein LA, Sonett JR (2011) The surgical management of stage I and stage II lung cancer. Surg Oncol Clin N Am 20: 701-720.
8. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285: 914-924.
9. Hsu WH, Hsu NY, Shen YY, Yen RF, Kao CH (2003) Differentiating solitary pulmonary metastases in patients with extrapulmonary neoplasmas using FDG-PET. Cancer Invest 21: 47-52.
10. Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT (2013) Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg 257: 364-370.
11. Kim K, Kim SJ, Kim IJ, Kim YS, Pak K, Kim H (2012) Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun 33: 613-620.
12. Kwee S, Song MA, Cheng I, Loo L, Tiirikainen M (2012) Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer. Clin Transl Sci 5: 65-70.
13. Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, Le QT, Wakelee HA, Donington JS, Graves EE, Loo Jr BW (2007) Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 69: 328-333.
14. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37: 646-650.
15. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y (2012) Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 39: 27-38.
16. Lin EC (2009) PET and PET/CT, A Clinical Guide, 2nd edn. Thieme: New York.
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 41: 1690-1696.
18. Messaoudi SE, Rolet F, Mouliere F, Thierry AR (2013) Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 424: 222-230.
19. Mok TS, D'arcangelo M, Califano R (2012) Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation. Drugs 72(Suppl 1): 3-10.
20. Nygaard AD (2012) Quantification of cell free DNA as a prognostic factor in advanced NSCLC. ESMO Congress 2012.
21. Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR (2012) Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 18: 2391-2401.
22. Rinaldi M, Cauchi C, Gridelli C (2006) First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 17(Suppl 5): v64-v67.
23. Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426-437.
24. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A (2012) Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 18: 1177-1185.
25. Steffensen KD, Waldstrom M, Grove A, Lund B, Pallisgard N, Jakobsen A (2011) Improved classification of epithelial ovarian cancer: results of 3 Danish cohorts. Int J Gynecol Cancer 9: 1592-1600.
26. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, Rossier A, Chen XQ, Anker P (2000) The origin and mechanism of circulating DNA. Ann NY Acad Sci 906: 161-168.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
28. Vadakara J, Borghaei H (2012) Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med 5: 113-123.
29. Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T, Ishibashi M, Hoshino T (2012) Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy. Eur J Radiol 81: 4179-4184.
30. Zhang H, Wroblewski K, Appelbaum D, Pu Y (2012) Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer. Int J Comput Assist Radiol Surg 8: 181-191.
31. Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y (2013) Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol 20: 32-40.